US20050020632A1 - Optical isomers of an iloperidone metabolite - Google Patents

Optical isomers of an iloperidone metabolite Download PDF

Info

Publication number
US20050020632A1
US20050020632A1 US10/488,128 US48812804A US2005020632A1 US 20050020632 A1 US20050020632 A1 US 20050020632A1 US 48812804 A US48812804 A US 48812804A US 2005020632 A1 US2005020632 A1 US 2005020632A1
Authority
US
United States
Prior art keywords
compound
acid addition
free base
addition salt
salt form
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/488,128
Inventor
Dominique Grimler
Hans Kalkman
Hegun Yin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to US10/488,128 priority Critical patent/US20050020632A1/en
Publication of US20050020632A1 publication Critical patent/US20050020632A1/en
Assigned to NOVARTIS AG reassignment NOVARTIS AG ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: YIN, HEQUN, KALKMAN, HANS O., GRIMLER, DOMINIQUE
Priority to US12/403,755 priority patent/US7977356B2/en
Priority to US13/096,015 priority patent/US8314129B2/en
Priority to US13/661,609 priority patent/US20130296366A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the present invention relates to novel isomers of a metabolite of Iloperidone, their preparation, their use as pharmaceuticals and pharmaceutical compositions containing them.
  • the invention relates to optical isomers of the metabolite P-88-8991 of Iloperidone.
  • Iloperidone is an atypical antipsychotic developed for the treatment of schizophrenia, having functional affinity for noradrenergic, dopaminergic and serotoninergic receptors. See for example Richelson E. and Souder T., Life Sciences, 68:29-39 (2000).
  • P-88-8991 is a major circulating metabolite of Iloperidone in human plasma, having the formula A See for example Mutlib AE et al., Drug Metab. Dispos; 23(9):951-964 (1995). P-88-8991 has been shown to have plasma levels in human about 1.5 fold higher than the parent drug. It is roughly as active as Iloperidone.
  • P-88-8991 consists of a mixture of two enantiomers which have never been disclosed in the literature. It has now surprisingly been found that humans produce only one enantiomer stereospecifically following administration of Iloperidone.
  • the invention provides the enantiomers (R)-P-88-8991 and (S)-P-88-8991 of formulae I and II in free base or acid addition salt form.
  • the invention provides a process for the production of the compounds of formulae I and II, comprising the reduction of Iloperidone of formula III with an optically active boran complex of formula IV
  • the compound (S)-1-(4- ⁇ 3-[4-(6-fluoro-benzo[d]isoxazol-3-yl)-piperidin-1-yl]-propoxy ⁇ -3-methoxy-phenyl)-ethanol of formula I is obtained using the boran complex of (3aR, 7R)-1-methyl-3,3-diphenyl-tetrahydro-pyrrolo[1,2-c][1,3,2]oxazaborole of formula IVa
  • the compound (R)-1-(4- ⁇ 3-[4-(6-fluoro-benzo[d]isoxazol-3-yl)-piperidin-1-yl]propoxy ⁇ -3-methoxy-phenyl)-ethanol of formula II is obtained using the boran complex of (3aS,7R)-1-methyl-3,3-diphenyl-tetrahydro-pyrrolo[1,2-c][1,3,2]oxazaborole of formula IVb
  • the reactions can be effected according to conventional methods, e.g. as described in the Examples.
  • Acid addition salts may be produced from the free bases in known manner, and vice-versa.
  • Suitable acid addition salts for use in accordance with the present invention include for example the hydrochloride.
  • the boran complexes used as starting materials can be produced from the corresponding compounds of formula Va and Vb according to known procedures, e.g. as described in the Examples.
  • agents of the invention exhibit valuable pharmacological properties when tested in vitro and in animals, and are therefore useful as pharmaceuticals.
  • the agents of the invention display high affinity for adrenergic ⁇ 1 and ⁇ 2c receptors (pK I 8.9 and 7.8 respectively, for the compound of formula I, and 9.2 and 7.7 respectively, for the compound of formula II), high affinity for 5 HT 2A and 5 HT 6 receptors (pK I 8.9 and 8.1 respectively, for the compound of formula I, and 8.9 and 7.8 respectively, for the compound of formula II) and moderate affinity for the D 2 family (pK I 7.4 to 7.6 for the compound of formula I and 7.4 to 7.8 for the compound of formula II).
  • Receptor affinity is determined with standard radioligand binding techniques, using human recombinant receptors and native rat brain receptors. Blockade of dopamine D 2 and noradrenergic ⁇ 2c receptors is tested in cell-lines using luciferase reporter gene assays based on 2 nd messenger responses.
  • the agents of the invention exhibit antipsychotic activity, as assessed in standard tests such as the amphetamine-induced hypermotility and the phencyclidine-induced hyperlocomotion tests.
  • the amphetamine-induced hypermotility test is performed according to the method described by Arnt J in Eur. J. Pharmacol. 283, 55-62 (1995).
  • the agents of the invention significantly inhibit the amphetamine-induced locomotion of the animals at doses of about 0.01 to about 10 mg/kg s.c.
  • the phencyclidine-induced hyperlocomotion test is performed according to a rat adaptation of the method described by Gleason SD and Shannon HE in Psychopharmacol. 129, 79-84 (1997).
  • the agents of the invention significantly block the phencyclidine-induced hyperlocomotion of the rats at doses of about 0.01 to about 10 mg/kg s.c.
  • the agents of the invention are therefore useful for the treatment of psychotic disorders such as schizophrenia and bipolar disorders.
  • the appropriate dosage will of course vary depending upon, for example, the compound employed, the host, the mode of administration and the nature and severity of the condition being treated. However, in general, satisfactory results in animals are indicated to be obtained at a daily dosage of from about 0.1 to about 500, preferably from about 0.5 to about 100 mg/kg animal body weight. In larger mammals, for example humans, an indicated daily dosage is in the range from about 1 to about 500, preferably from about 1 to about 300 mg of an agent of the invention, conveniently administered, for example, in divided doses up to four times a day or in sustained release form.
  • the agent of the invention may be administered by any conventional route, in particular enterally, preferably orally, for example in the form of tablets or capsules, or parenterally, for example in the form of injectable solutions or suspensions.
  • agents of the invention may alternatively be administered e.g. topically in the form of a cream, gel or the like, or by inhalation, e.g. in dry powder form.
  • compositions comprising an agent of the invention include, e.g. a solid dispersion, an aqueous solution, e.g. containing a solubilising agent, a microemulsion and a suspension of an agent of the invention.
  • the composition may be buffered to a pH in the range of e.g. from 3.5 to 9.5, by a suitable buffer.
  • the agents of the invention can be administered either alone or in combination with other pharmaceutical agents effective in the treatment of psychotic disorders such as schizophrenia or bipolar disorders.
  • the present invention thus provides a combination comprising a therapeutically effective amount of an agent of the invention and a second drug substance, for simultaneous or sequential administration.
  • the present invention also provides an agent of the invention, for use as a pharmaceutical, e.g. for the treatment of psychotic disorders.
  • the present invention furthermore provides a pharmaceutical composition
  • a pharmaceutical composition comprising an agent of the invention in association with at least one pharmaceutical carrier or diluent.
  • Such compositions may be manufactured in conventional manner.
  • Unit dosage forms contain, for example, from about 0.25 to about 150, preferably from 0.25 to about 25 mg of a compound according to the invention.
  • the present invention provides the use of an agent of the invention, for the manufacture of a medicament for the treatment of psychotic disorders.
  • the present invention provides a method for the treatment of psychotic disorders, in a subject in need of such treatment, which comprises administering to such subject a therapeutically effective amount of an agent of the invention.
  • the boran complex used as starting material can be obtained as follows:
  • This compound is produced in analogy to Example 1, using boran complex of (3aS, 7R)-1-methyl-3,3-diphenyl-tetrahydro-pyrrolo[1,2-c][1,3,2]oxazaborole.

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)

Abstract

The invention provides compounds of formulae (I) and (II), their preparation and their use as pharmaceuticals.
Figure US20050020632A1-20050127-C00001

Description

  • The present invention relates to novel isomers of a metabolite of Iloperidone, their preparation, their use as pharmaceuticals and pharmaceutical compositions containing them.
  • More particularly, the invention relates to optical isomers of the metabolite P-88-8991 of Iloperidone.
  • Iloperidone is an atypical antipsychotic developed for the treatment of schizophrenia, having functional affinity for noradrenergic, dopaminergic and serotoninergic receptors. See for example Richelson E. and Souder T., Life Sciences, 68:29-39 (2000).
  • P-88-8991 is a major circulating metabolite of Iloperidone in human plasma, having the formula A
    Figure US20050020632A1-20050127-C00002
    See for example Mutlib AE et al., Drug Metab. Dispos; 23(9):951-964 (1995). P-88-8991 has been shown to have plasma levels in human about 1.5 fold higher than the parent drug. It is roughly as active as Iloperidone.
  • P-88-8991 consists of a mixture of two enantiomers which have never been disclosed in the literature. It has now surprisingly been found that humans produce only one enantiomer stereospecifically following administration of Iloperidone.
  • In the first aspect, the invention provides the enantiomers (R)-P-88-8991 and (S)-P-88-8991 of formulae I and II
    Figure US20050020632A1-20050127-C00003
    in free base or acid addition salt form.
  • In a further aspect, the invention provides a process for the production of the compounds of formulae I and II, comprising the reduction of Iloperidone of formula III
    Figure US20050020632A1-20050127-C00004
    with an optically active boran complex of formula IV
    Figure US20050020632A1-20050127-C00005
  • The compound (S)-1-(4-{3-[4-(6-fluoro-benzo[d]isoxazol-3-yl)-piperidin-1-yl]-propoxy}-3-methoxy-phenyl)-ethanol of formula I is obtained using the boran complex of (3aR, 7R)-1-methyl-3,3-diphenyl-tetrahydro-pyrrolo[1,2-c][1,3,2]oxazaborole of formula IVa
    Figure US20050020632A1-20050127-C00006
    whereas the compound (R)-1-(4-{3-[4-(6-fluoro-benzo[d]isoxazol-3-yl)-piperidin-1-yl]propoxy}-3-methoxy-phenyl)-ethanol of formula II is obtained using the boran complex of (3aS,7R)-1-methyl-3,3-diphenyl-tetrahydro-pyrrolo[1,2-c][1,3,2]oxazaborole of formula IVb
    Figure US20050020632A1-20050127-C00007
  • The reactions can be effected according to conventional methods, e.g. as described in the Examples.
  • Working up the reaction mixtures and purification of the compounds thus obtained may be carried out in accordance to known procedures.
  • Acid addition salts may be produced from the free bases in known manner, and vice-versa. Suitable acid addition salts for use in accordance with the present invention include for example the hydrochloride.
  • The boran complexes used as starting materials can be produced from the corresponding compounds of formula Va and Vb
    Figure US20050020632A1-20050127-C00008
    according to known procedures, e.g. as described in the Examples.
  • The starting materials of formulae Va and Vb are known.
  • The compounds of formulae I and II and their pharmaceutically acceptable acid addition salts, hereinafter referred to as agents of the invention, exhibit valuable pharmacological properties when tested in vitro and in animals, and are therefore useful as pharmaceuticals.
  • In particular the agents of the invention display high affinity for adrenergic α1 and α2c receptors (pKI 8.9 and 7.8 respectively, for the compound of formula I, and 9.2 and 7.7 respectively, for the compound of formula II), high affinity for 5 HT2A and 5 HT6 receptors (pKI 8.9 and 8.1 respectively, for the compound of formula I, and 8.9 and 7.8 respectively, for the compound of formula II) and moderate affinity for the D2 family (pKI 7.4 to 7.6 for the compound of formula I and 7.4 to 7.8 for the compound of formula II).
  • Receptor affinity is determined with standard radioligand binding techniques, using human recombinant receptors and native rat brain receptors. Blockade of dopamine D2 and noradrenergic α2c receptors is tested in cell-lines using luciferase reporter gene assays based on 2nd messenger responses.
  • In vivo, the agents of the invention exhibit antipsychotic activity, as assessed in standard tests such as the amphetamine-induced hypermotility and the phencyclidine-induced hyperlocomotion tests.
  • The amphetamine-induced hypermotility test is performed according to the method described by Arnt J in Eur. J. Pharmacol. 283, 55-62 (1995). In this test, the agents of the invention significantly inhibit the amphetamine-induced locomotion of the animals at doses of about 0.01 to about 10 mg/kg s.c.
  • The phencyclidine-induced hyperlocomotion test is performed according to a rat adaptation of the method described by Gleason SD and Shannon HE in Psychopharmacol. 129, 79-84 (1997). In this test, the agents of the invention significantly block the phencyclidine-induced hyperlocomotion of the rats at doses of about 0.01 to about 10 mg/kg s.c.
  • The agents of the invention are therefore useful for the treatment of psychotic disorders such as schizophrenia and bipolar disorders.
  • For the above-mentioned indications, the appropriate dosage will of course vary depending upon, for example, the compound employed, the host, the mode of administration and the nature and severity of the condition being treated. However, in general, satisfactory results in animals are indicated to be obtained at a daily dosage of from about 0.1 to about 500, preferably from about 0.5 to about 100 mg/kg animal body weight. In larger mammals, for example humans, an indicated daily dosage is in the range from about 1 to about 500, preferably from about 1 to about 300 mg of an agent of the invention, conveniently administered, for example, in divided doses up to four times a day or in sustained release form.
  • The agent of the invention may be administered by any conventional route, in particular enterally, preferably orally, for example in the form of tablets or capsules, or parenterally, for example in the form of injectable solutions or suspensions.
  • The agents of the invention may alternatively be administered e.g. topically in the form of a cream, gel or the like, or by inhalation, e.g. in dry powder form.
  • Examples for compositions comprising an agent of the invention include, e.g. a solid dispersion, an aqueous solution, e.g. containing a solubilising agent, a microemulsion and a suspension of an agent of the invention. The composition may be buffered to a pH in the range of e.g. from 3.5 to 9.5, by a suitable buffer.
  • The agents of the invention can be administered either alone or in combination with other pharmaceutical agents effective in the treatment of psychotic disorders such as schizophrenia or bipolar disorders. The present invention thus provides a combination comprising a therapeutically effective amount of an agent of the invention and a second drug substance, for simultaneous or sequential administration.
  • In accordance with the foregoing, the present invention also provides an agent of the invention, for use as a pharmaceutical, e.g. for the treatment of psychotic disorders.
  • The present invention furthermore provides a pharmaceutical composition comprising an agent of the invention in association with at least one pharmaceutical carrier or diluent. Such compositions may be manufactured in conventional manner. Unit dosage forms contain, for example, from about 0.25 to about 150, preferably from 0.25 to about 25 mg of a compound according to the invention.
  • Moreover the present invention provides the use of an agent of the invention, for the manufacture of a medicament for the treatment of psychotic disorders.
  • In still a further aspect the present invention provides a method for the treatment of psychotic disorders, in a subject in need of such treatment, which comprises administering to such subject a therapeutically effective amount of an agent of the invention.
  • The following examples illustrate the invention.
    • EXAMPLE 1 (S)-1-(4-{3-[4-(6-Fluoro-benzo[d]isoxazol-3-yl)-piperidin-1-yl]-propoxy}-3-methoxy-phenyl)-ethanol
  • 56.36 g of boran complex of (3aR, 7R)-1-methyl-3,3-diphenyl-tetrahydro-pyrrolo[1,2-c][1,3,2]oxazaborole (1 equivalent) is dissolved under nitrogen in methylenchloride, and the solution is cooled to 0° C. A 1M solution of 1-(4-{3-[4-(6-fluoro-benzo[d]isoxazol-3-yl)-piperidin-1-yl]-propoxy}-3-methoxy-phenyl)-ethanone (iloperidone; 1 equivalent) in methylenchloride is added via a dropping funnel over 90 minutes while the internal temperature is maintained at 0° C.±2° C. After the addition is complete, the mixture is stirred at 0° C. for 20 hours. The reaction mixture is then poured into precooled methanol (0-5° C.) during 1 hour. The solution is warmed to room temperature and stirred until the H2 evolution ceases. The solution is concentrated by distillation and the residue dried in vacuum, treated with methanol and stirred for about 1 hour at 50° C. and an additional hour at 0° C. The product is isolated by filtration and dried under reduced pressure for 3 hours at 50° C. The title compound is obtained (white crystals).
  • [α]D 20−19.3° (c=1 in chloroform)
  • Mp: 138.2-138.8° C.
  • The boran complex used as starting material can be obtained as follows:
  • 200 ml of a solution of (3aR, 7R)-1-methyl-3,3-diphenyl-tetrahydro-pyrrolo[1,2-c][1,3,2]oxazaborole (1M in toluene) is stirred at room temperature under nitrogen. 1.2 equivalent borane-dimethylsulfide complex is added with a syringe. The solution is stirred for 2 further hours at room temperature. The borane complex is then crystallised by addition of 4 vol dry hexane and cooling to −12° C. for 1.5 hour. The product is isolated by filtration in a sintered glass funnel and dried in vacuum at 40° C. The boran complex is obtained/white crystals).
    • EXAMPLE 2 (R)-1-(4-{3-[4-(6-Fluoro-benzo[d]isoxazol-3-yl)-piperidin-1-yl]-propoxy}-3-methoxy-phenlyl)-ethanol
  • This compound is produced in analogy to Example 1, using boran complex of (3aS, 7R)-1-methyl-3,3-diphenyl-tetrahydro-pyrrolo[1,2-c][1,3,2]oxazaborole.
  • [α]D 20=+18.4° (c=1 in chloroform)
  • Mp: 137.9-138.3° C.

Claims (18)

1. (R)-1-(4-{3-[4-(6-Fluoro-benzo[d]isoxazol-3-yl}-piperidin-1-yl]-propoxy}-3-methoxy-phenyl)-ethanol of formula I
Figure US20050020632A1-20050127-C00009
in free base or acid addition salt form.
2. (S)-1-(4-{3-[4-(6-Fluoro-benzo[d]isoxazol-3-yl)-piperidin-1-yl]-propoxy}-3-methoxy-phenyl)-ethanol of formula II
Figure US20050020632A1-20050127-C00010
in free base or acid addition salt form.
3. A process for the production of the compound of formula I according to claim 1, and its salts, comprising the reduction of Iloperidone of formula III
Figure US20050020632A1-20050127-C00011
with an optically active boran complex of formula IV
Figure US20050020632A1-20050127-C00012
and recovering the resulting compound in free base or acid addition salt form.
4. A compound of claim 1 in free base or pharmaceutically acceptable acid addition salt form, for use as a pharmaceutical.
5. A compound of claim 1 in free base or pharmaceutically acceptable acid addition salt form, for use in the treatment of psychotic disorders.
6. A pharmaceutical composition comprising a compound of claim 1 in free base or pharmaceutically acceptable acid addition salt form, in association with a pharmaceutical carrier or diluent.
7. The use of a compound of claim 1 in free base or pharmaceutically acceptable acid addition salt form, as a pharmaceutical for the treatment of psychotic disorders.
8. The use of a compound of claim 1 free base or pharmaceutically acceptable acid addition salt form, for the manufacture of a medicament for the treatment of psychotic disorders.
9. A method for the treatment of psychotic disorders in a subject in need of such treatment, which comprises administering to such subject a therapeutically effective amount of a compound of claim 1 in free base or pharmaceutically acceptable acid addition salt form.
10. A combination comprising a therapeutically effective amount of a compound of claim 1 in free base or pharmaceutically acceptable acid addition salt form, and a second drug substance, for simultaneous or sequential administration.
11. A process for the production of the compound of formula II according to claim 2, and its salts, comprising the reduction of Iloperidone of formula III
Figure US20050020632A1-20050127-C00013
with an optically active boran complex of formula IV
Figure US20050020632A1-20050127-C00014
and recovering the resulting compound in free base or acid addition salt form.
12. A compound of claim 2 in free base or pharmaceutically acceptable acid addition salt form, for use as a pharmaceutical.
13. A compound of claim 2 in free base or pharmaceutically acceptable acid addition salt form, for use in the treatment of psychotic disorders.
14. A pharmaceutical composition comprising a compound of claim 2 in free base or pharmaceutically acceptable acid addition salt form, in association with a pharmaceutical carrier or diluent.
15. The use of a compound of claim 2 in free base or pharmaceutically acceptable acid addition salt form, as a pharmaceutical for the treatment of psychotic disorders.
16. The use of a compound of claim 2 in free base or pharmaceutically acceptable acid addition salt form, for the manufacture of a medicament for the treatment of psychotic disorders.
17. A method for the treatment of psychotic disorders in a subject in need of such treatment, which comprises administering to such subject a therapeutically effective amount of a compound of claim 2 in free base or pharmaceutically acceptable acid addition salt form.
18. A combination comprising a therapeutically effective amount of a compound of claim 2 in free base or pharmaceutically acceptable acid addition salt form, and a second drug substance, for simultaneous or sequential administration.
US10/488,128 2001-08-31 2002-08-30 Optical isomers of an iloperidone metabolite Abandoned US20050020632A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US10/488,128 US20050020632A1 (en) 2001-08-31 2002-08-30 Optical isomers of an iloperidone metabolite
US12/403,755 US7977356B2 (en) 2001-08-31 2009-03-13 Optical isomers of an Iloperidone metabolite
US13/096,015 US8314129B2 (en) 2001-08-31 2011-04-28 Optical isomers of an iloperidone metabolite
US13/661,609 US20130296366A1 (en) 2001-08-31 2012-10-26 Optical isomers of an iloperidone metabolite

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US31639001P 2001-08-31 2001-08-31
US60316390 2001-08-31
PCT/EP2002/009700 WO2003020707A1 (en) 2001-08-31 2002-08-30 Optical isomers of an iloperidone metabolite
US10/488,128 US20050020632A1 (en) 2001-08-31 2002-08-30 Optical isomers of an iloperidone metabolite

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/403,755 Continuation US7977356B2 (en) 2001-08-31 2009-03-13 Optical isomers of an Iloperidone metabolite

Publications (1)

Publication Number Publication Date
US20050020632A1 true US20050020632A1 (en) 2005-01-27

Family

ID=23228843

Family Applications (4)

Application Number Title Priority Date Filing Date
US10/488,128 Abandoned US20050020632A1 (en) 2001-08-31 2002-08-30 Optical isomers of an iloperidone metabolite
US12/403,755 Expired - Lifetime US7977356B2 (en) 2001-08-31 2009-03-13 Optical isomers of an Iloperidone metabolite
US13/096,015 Expired - Lifetime US8314129B2 (en) 2001-08-31 2011-04-28 Optical isomers of an iloperidone metabolite
US13/661,609 Abandoned US20130296366A1 (en) 2001-08-31 2012-10-26 Optical isomers of an iloperidone metabolite

Family Applications After (3)

Application Number Title Priority Date Filing Date
US12/403,755 Expired - Lifetime US7977356B2 (en) 2001-08-31 2009-03-13 Optical isomers of an Iloperidone metabolite
US13/096,015 Expired - Lifetime US8314129B2 (en) 2001-08-31 2011-04-28 Optical isomers of an iloperidone metabolite
US13/661,609 Abandoned US20130296366A1 (en) 2001-08-31 2012-10-26 Optical isomers of an iloperidone metabolite

Country Status (10)

Country Link
US (4) US20050020632A1 (en)
EP (2) EP1425272B1 (en)
JP (6) JP2005504783A (en)
AT (1) ATE518845T1 (en)
CY (2) CY1112039T1 (en)
DK (2) DK2305656T3 (en)
ES (2) ES2398434T3 (en)
HK (2) HK1066536A1 (en)
PT (2) PT2305656E (en)
WO (1) WO2003020707A1 (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011077239A2 (en) 2009-12-23 2011-06-30 Lupin Limited Slow release pharmaceutical compositions of iloperidone
US20110172272A1 (en) * 2003-10-01 2011-07-14 Joachim Nozulak Benzisoxazoles
US8524561B2 (en) 2008-11-05 2013-09-03 Micron Technology, Inc. Methods of forming a plurality of transistor gates, and methods of forming a plurality of transistor gates having at least two different work functions
US8692320B2 (en) 2006-05-11 2014-04-08 Micron Technology, Inc. Recessed memory cell access devices and gate electrodes
US8710583B2 (en) 2006-05-11 2014-04-29 Micron Technology, Inc. Dual work function recessed access device and methods of forming
WO2020172506A1 (en) * 2019-02-21 2020-08-27 Obi Pharma Inc. Methods of making high enantioselective secondary alcohols

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60238780D1 (en) 2001-10-30 2011-02-10 Novartis Ag DEPOT FORMULATIONS OF ILOPERIDONE AND A STAR-TERM POLYMER
ES2307919T3 (en) 2002-03-27 2008-12-01 Glaxo Group Limited DERIVATIVES OF QUINOLINA AND ITS USE AS LIGANDS OF 5-HT6.
GB0216416D0 (en) * 2002-07-15 2002-08-21 Novartis Ag Organic compounds
PT1558582E (en) 2003-07-22 2006-05-31 Arena Pharm Inc DIARIL- AND ARIL-HETEROARIL-UREA DERIVATIVES AS SEROTONIN 5-HT2A RECEPTOR MODULES USEFUL FOR PROPHYLAXIS AND TREATMENT OF RELEVANT DISORDERS
US20100063093A1 (en) 2007-03-28 2010-03-11 Curt Wolfgang Methods for the administration of iloperidone
CA3113166A1 (en) 2004-09-30 2006-04-13 Vanda Pharmaceuticals Inc. Methods for the administration of iloperidone
KR20090029200A (en) * 2006-05-22 2009-03-20 반다 파마슈티칼즈, 인코퍼레이티드. Treatment for depressive disorders
US20150259747A1 (en) 2007-03-29 2015-09-17 Vanda Pharmaceuticals Inc. Method of predicting a predisposition to qt prolongation
WO2008121899A2 (en) 2007-03-29 2008-10-09 Vanda Pharmaceuticals Inc. Method of predicting a predisposition to qt prolongation
US8198305B2 (en) 2007-04-13 2012-06-12 Concert Pharmaceuticals Inc. 1,2-benzisoxazol-3-yl compounds
WO2008144599A2 (en) 2007-05-18 2008-11-27 Vanda Pharmaceuticals Inc. Genetic markers for efficacy of iloperidone in the treatment of psychotic symptoms
US8652776B2 (en) 2007-09-10 2014-02-18 Vanda Pharmaceuticals, Inc. Prediction of QT prolongation based on SNP genotype
EP2254564A1 (en) 2007-12-12 2010-12-01 Glaxo Group Limited Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline
WO2009076664A1 (en) 2007-12-13 2009-06-18 Vanda Pharmaceuticals Inc. Method and composition for treating a serotonin receptor-mediated condition
ES2527515T3 (en) 2007-12-13 2015-01-26 Vanda Pharmaceuticals Inc. Method and composition to treat a condition mediated by an alpha adrenoceptor
US20110061014A1 (en) 2008-02-01 2011-03-10 Energyhub Interfacing to resource consumption management devices
US20110021538A1 (en) 2008-04-02 2011-01-27 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
US9126946B2 (en) 2008-10-28 2015-09-08 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto
US9074255B2 (en) 2009-04-06 2015-07-07 Vanda Pharmaceuticals, Inc. Method of predicting a predisposition to QT prolongation
HUE037724T2 (en) 2009-04-06 2018-09-28 Vanda Pharmaceuticals Inc Method of treatment based on polymorphisms of the kcnq1 gene
WO2010117943A1 (en) 2009-04-06 2010-10-14 Vanda Pharmaceuticals, Inc. Method of predicting a predisposition to qt prolongation based on bai3 gene sequence or product thereof
EP2416778B1 (en) 2009-04-06 2016-03-02 Vanda Pharmaceuticals Inc. Method of predicting a predisposition to qt prolongation based on abcc2 gene sequence or product thereof
US9000221B2 (en) 2010-09-07 2015-04-07 Symed Labs Limited Processes for the preparation of 4′-[3-[4-(6-Fluoro-1 ,2-benzisoxazol-3-yl)piperidino]propoxy]-3′-methoxyacetophenone and intermediates thereof
WO2012063269A2 (en) 2010-11-12 2012-05-18 Cadila Healthcare Limited Process for preparing iloperidone
US10874659B2 (en) * 2012-03-14 2020-12-29 Vanda Pharmaceuticals Inc. Iloperidone metabolite for use in the treatment of psychiatric disorders
BR112017017608A2 (en) 2015-02-17 2018-05-08 Vanda Pharmaceuticals Inc methods for treating schizophrenia or a symptom of schizophrenia, to prevent a schizophrenic relapse and to maintain the effect of iloperidone for schizophrenia.
RU2017145976A (en) 2015-06-12 2019-07-15 Аксовант Сайенсиз Гмбх Diaryl- and arylheteroarylurea derivatives applicable for the prevention and treatment of behavioral disturbances during the REM phase of sleep
KR20180064373A (en) 2015-07-15 2018-06-14 엑소반트 사이언시즈 게엠베하 Diaryl and aryl heteroaryl urea derivatives as modulators of 5-HT2A serotonin receptors useful for the prevention and treatment of hallucinations associated with neurodegenerative diseases
US11607408B2 (en) 2019-10-15 2023-03-21 Vanda Pharmaceuticals Inc. Method of treatment of schizophrenia
WO2023201182A1 (en) 2022-04-13 2023-10-19 Vanda Pharmaceuticals Inc. Treatment of parkinson's disease and parkinson's disease psychosis
WO2024137439A1 (en) 2022-12-19 2024-06-27 Vanda Pharmaceuticals Inc. Dosage regime of iloperidone for treating bipolar i disorder and schizophrenia

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4804663A (en) * 1985-03-27 1989-02-14 Janssen Pharmaceutica N.V. 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles
US5158952A (en) * 1988-11-07 1992-10-27 Janssen Pharmaceutica N.V. 3-[2-[4-(6-fluoro-1,2-benzisoxozol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9 tetrahydro-9-hydroxy-2-methyl-4H-pyrido [1,2-a]pyrimidin-4-one, compositions and method of use

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69021645T2 (en) 1989-05-19 1996-02-22 Hoechst-Roussel Pharmaceuticals Inc., Somerville, N.J. N- (aryloxyalkyl) heteroarylpiperidines and heteroarylpiperazines, processes for their preparation and their use as medicaments.
US5364866A (en) * 1989-05-19 1994-11-15 Hoechst-Roussel Pharmaceuticals, Inc. Heteroarylpiperidines, pyrrolidines and piperazines and their use as antipsychotics and analetics
US5776963A (en) 1989-05-19 1998-07-07 Hoechst Marion Roussel, Inc. 3-(heteroaryl)-1- (2,3-dihydro-1h-isoindol-2-yl)alkyl!pyrrolidines and 3-(heteroaryl)-1- (2,3-dihydro-1h-indol-1-yl)alkyl!pyrrolidines and related compounds and their therapeutic untility
JPH05286868A (en) 1992-04-03 1993-11-02 Kiyoshi Okawa Carcinostatic agent complex and its screening method
US5889006A (en) * 1995-02-23 1999-03-30 Schering Corporation Muscarinic antagonists
KR100335169B1 (en) * 1997-07-03 2002-05-04 야마모토 카즈모토 Novel Tricyclic Compounds Having Saturated Rings and Medicinal Compositions Containing the Same
AU2003268026A1 (en) 2002-07-30 2004-02-16 Peter Migaly Combination therapy for depression, prevention of suicide, and varous medical and psychiatric conditions

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4804663A (en) * 1985-03-27 1989-02-14 Janssen Pharmaceutica N.V. 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles
US5158952A (en) * 1988-11-07 1992-10-27 Janssen Pharmaceutica N.V. 3-[2-[4-(6-fluoro-1,2-benzisoxozol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9 tetrahydro-9-hydroxy-2-methyl-4H-pyrido [1,2-a]pyrimidin-4-one, compositions and method of use

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110172272A1 (en) * 2003-10-01 2011-07-14 Joachim Nozulak Benzisoxazoles
US8692320B2 (en) 2006-05-11 2014-04-08 Micron Technology, Inc. Recessed memory cell access devices and gate electrodes
US8710583B2 (en) 2006-05-11 2014-04-29 Micron Technology, Inc. Dual work function recessed access device and methods of forming
US9543433B2 (en) 2006-05-11 2017-01-10 Micron Technology, Inc. Dual work function recessed access device and methods of forming
US8524561B2 (en) 2008-11-05 2013-09-03 Micron Technology, Inc. Methods of forming a plurality of transistor gates, and methods of forming a plurality of transistor gates having at least two different work functions
WO2011077239A2 (en) 2009-12-23 2011-06-30 Lupin Limited Slow release pharmaceutical compositions of iloperidone
WO2020172506A1 (en) * 2019-02-21 2020-08-27 Obi Pharma Inc. Methods of making high enantioselective secondary alcohols
CN114941015A (en) * 2019-02-21 2022-08-26 深圳艾欣达伟医药科技有限公司 Method for producing secondary alcohol with high mirror image selectivity
US11773118B2 (en) 2019-02-21 2023-10-03 Obi Pharma, Inc. Methods of making high enantioselective secondary alcohols

Also Published As

Publication number Publication date
HK1156309A1 (en) 2012-09-07
ES2370634T3 (en) 2011-12-21
PT1425272E (en) 2011-10-19
ATE518845T1 (en) 2011-08-15
HK1066536A1 (en) 2005-03-24
PT2305656E (en) 2013-01-10
DK1425272T3 (en) 2011-11-21
CY1113550T1 (en) 2016-06-22
JP2005504783A (en) 2005-02-17
US20090176739A1 (en) 2009-07-09
EP1425272B1 (en) 2011-08-03
JP2010100633A (en) 2010-05-06
US8314129B2 (en) 2012-11-20
JP2015227368A (en) 2015-12-17
EP1425272A1 (en) 2004-06-09
EP2305656B1 (en) 2012-10-24
DK2305656T3 (en) 2013-02-11
JP2015214577A (en) 2015-12-03
WO2003020707A1 (en) 2003-03-13
ES2398434T3 (en) 2013-03-19
JP2013116905A (en) 2013-06-13
EP2305656A1 (en) 2011-04-06
US20110201646A1 (en) 2011-08-18
CY1112039T1 (en) 2015-11-04
US20130296366A1 (en) 2013-11-07
US7977356B2 (en) 2011-07-12
ES2398434T8 (en) 2017-10-09
JP2013227335A (en) 2013-11-07

Similar Documents

Publication Publication Date Title
US8314129B2 (en) Optical isomers of an iloperidone metabolite
US20200131166A1 (en) Benzisoxazoles
US20050209228A1 (en) 8-{4-[3-(5-fluoro-1H-indol-3-yl)-propyl]-piperazin-1-yl}-2-methyl-4H-benzo[1,4]oxazin-3-one mesylate with high affinity for the dopamine D2 receptor and the serotonin reuptake site
EA011636B1 (en) Kynurenic acid amide derivatives as antagonists of nr2b subtype of nmda receptor
US6930118B2 (en) 3-Oxadiazol-5-yl-1-aminoalkyl-1h-indole derivatives
JPS63264481A (en) Novel piperidines, drug composition and manufacture
JP2005527500A (en) Heterocyclic compounds with affinity at 5HT1-type receptors and their use in therapy
EP0920423B1 (en) Disubstituted morpholine, oxazepine or thiazepine derivatives, their preparation and their use as dopamine d4 receptor antagonists
JP2005529073A (en) Heterocyclylmethylpiperidine and -piperazine having affinity at the 5HT-1 type receptor
EP1828168A2 (en) Tetrahydropyridin-4-yl indoles with a combination of affinity for dopamine-d2 receptors and serotonin reuptake sites
US20060122206A1 (en) Tetrahydropyridin-4-yl indoles with a combination of affinity for dopamine-D2 receptors and serotonin reuptake sites

Legal Events

Date Code Title Description
AS Assignment

Owner name: NOVARTIS AG, SWITZERLAND

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:GRIMLER, DOMINIQUE;KALKMAN, HANS O.;YIN, HEQUN;REEL/FRAME:018935/0007;SIGNING DATES FROM 20040212 TO 20040304

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION